Novartis

Anthos Therapeutics is a biopharmaceutical company that specializes in the treatment of cardiovascular and metabolic diseases. The company was founded by a world-class executive team with extensive experience in the development and commercialization of CVM disease therapies.

Kate Therapeutics is a biotechnology company dedicated to developing adeno-associated virus (AAV)-based gene therapies for genetically defined muscle and heart diseases. The company employs advanced technology platforms to enhance tissue-specific delivery and gene regulation, overcoming significant challenges associated with current gene therapies. By utilizing innovative capsids, Kate Therapeutics achieves superior muscle transduction and effectively de-targets the liver, allowing for more efficient tissue transduction at lower viral doses. This approach addresses key limitations in muscle gene delivery, aiming to improve treatment outcomes for patients with muscle and heart conditions.

Borealis Biosciences is a discovery-stage biotechnology company focused on developing next-generation RNA-based medicines specifically for kidney diseases. The company utilizes its expertise in molecular and cellular biology, chemistry, and analytical capabilities to identify target opportunities within different patient subsets affected by kidney conditions. By refining methods for delivering RNA medicines to specific cell types, Borealis Biosciences aims to tackle significant unmet medical needs in the treatment of kidney diseases.

Dren Bio is a biotechnology company that specializes in protein engineering technologies designed to target and deplete pathogenic cells, protein aggregates, and other disease-causing agents. With a focus on hematologic neoplasms, solid cancers, autoimmune disorders, and diseases related to protein aggregation, the company aims to provide innovative solutions for healthcare professionals in their efforts to combat various serious diseases. Operating under a holding company model, Dren Bio develops multiple projects as standalone assets, seeking to create value through its diverse portfolio of biotechnology initiatives.

CatalYm GmbH, founded in 2016 and based in Munich, Germany, is a biotechnology company focused on developing innovative immunotherapies for cancer patients. The company has identified GDF-15 as a key regulator of the immune system within the tumor microenvironment. By neutralizing GDF-15, CatalYm aims to enhance the immune response against solid tumors, potentially leading to meaningful clinical outcomes. Its CTL-002 program is designed to demonstrate clinical proof-of-concept across multiple solid tumor indications, offering the prospect of expanding treatment options for cancer patients. Through its approach, CatalYm seeks to transform the tumor microenvironment, making tumors more accessible to the immune system and improving both survival rates and quality of life for patients.

Mariana Oncology is a biotechnology company focused on developing radiopharmaceuticals designed to target cancer cells using radioactive drugs. The company leverages expertise in ligand discovery, radiochemistry, and radiobiology, along with oncology translational and clinical research, to create a diverse pipeline aimed at treating various solid tumor types. By advancing the use of radiomedicines, Mariana Oncology seeks to enhance treatment options for medical professionals in their fight against cancer.

Calypso Biotech is an innovative biopharmaceutical company based in Geneva, Switzerland and founded in 2013 as a spin-off from Merck Serono, a global leader in auto-immune diseases and biologics. Calypso Biotech was initially financed through a 2.5 million euro seed-fund managed by MS Ventures.A highly experienced management team with strong expertise in drug development and an extensive scientific and industry network manages Calypso Biotech. They operate as a nimble, semi-virtual organization in order to create substantial added value for their investors from a portfolio of unique proprietary antibody candidates.

Yseop is an artificial intelligence software company that specializes in natural language generation (NLG), primarily serving the financial and life sciences sectors. Its platform automates the creation of intelligent and non-repetitive text in multiple languages, including English, German, Dutch, French, Spanish, and Japanese. By leveraging its patented technology, Yseop enhances the efficiency of business teams through automation of various tasks such as lead generation, up-selling, cross-selling, and the preparation of meeting reports and customer intelligence summaries. This innovation allows sales and marketing teams to focus more on customer interactions rather than administrative duties, significantly reducing costs and accelerating the sales process. Yseop offers its solutions as software as a service (SaaS) or as an annual term license, which can be hosted on a company's servers.

Octave is a clinical platform developer focused on transforming the care landscape for multiple sclerosis and other neurodegenerative diseases. The company's platform generates, analyzes, and integrates data to provide a comprehensive approach aimed at reducing the overall cost of care. By optimizing healthcare medications and utilization, Octave enables pharmaceutical companies to enhance the entire lifecycle of drug discovery, clinical trials, and post-marketing processes through the use of real-world evidence. This innovative approach seeks to improve patient outcomes while streamlining healthcare practices.

DTx Pharma, LLC is a biotechnology company focused on developing and commercializing fatty acid-conjugated peptide therapeutics for patients with rare and chronic diseases. The company specializes in RNA-based therapeutics, utilizing a delivery technology platform that enhances the distribution of nucleic acid drugs to various tissues and organ systems beyond the liver. This innovative approach addresses limitations associated with previous-generation RNA delivery methods, such as poor pharmacokinetics and inadequate cellular uptake. DTx Pharma's products target conditions including retinitis pigmentosa, Duchenne muscular dystrophy, and central nervous system disorders. Founded in 2017 and based in San Diego, California, DTx Pharma aims to provide personalized treatment options across multiple therapeutic areas.

Medtech Africa provides a medical platform (Forcardio) that enables caregivers to use health monitoring to manage and improve the care of their patients. We provide easy access to continuous medical care for cardiovascular disease management and care in emerging markets. We provide cost-effective and simplified tools that provide proactive, personalized, and timely information about people living with chronic conditions such as diabetes, hypertension, and heart failure.

Chinook Therapeutics is a clinical-stage biotechnology company based in Seattle, Washington, that specializes in developing precision medicines for kidney diseases. The company's lead program is atrasentan, an investigational endothelin receptor antagonist currently undergoing Phase III trials for IgA nephropathy and other glomerular diseases. Additionally, Chinook is evaluating BION-1301, an anti-APRIL monoclonal antibody, in a Phase Ib trial for IgA nephropathy. The company is also advancing CHK-336, a preclinical candidate targeting an undisclosed ultra-orphan kidney disease, along with research initiatives focused on other rare and severe chronic kidney conditions, including polycystic kidney disease. Chinook Therapeutics aims to address significant unmet medical needs in the field of nephrology through its innovative product pipeline.

RxLightning is a digital platform focused on improving access to specialty medications by automating and streamlining the enrollment process. The company addresses the complexities associated with starting patients on specialty therapies across various fields, including addiction medicine, cardiology, endocrinology, and dermatology. By digitizing manual procedures, RxLightning reduces the burden of paperwork and enhances communication among healthcare providers, ultimately accelerating patients' speed to therapy. This innovative approach allows for a more efficient and effective management of specialty prescriptions, benefiting both healthcare professionals and patients alike.

Yuweitek is a company that specializes in the research and development of advanced technologies for automotive safety and connectivity. It focuses on the integration of software and hardware applications related to Beidou satellite positioning, car communication, driving record systems, intelligent video algorithms, and network connection technologies. The company has developed a range of products, including new energy vehicle terminals, satellite positioning vehicle wireless terminals, multimedia car driving recorders, and high-definition cameras, organized into nine product series. In addition to its product offerings, Yuweitek provides various industry platform management software systems to enhance its clients' operational efficiency and safety in car networking and remote monitoring.

Patientory, Inc. is a healthcare technology company based in Atlanta, Georgia, established in 2015. It offers a health data management platform that enables individuals to securely store, manage, and share their health information. The platform empowers patients to take control of their medical records and chronic illness management while facilitating better communication and support between healthcare providers and patients. By integrating a blockchain-enabled network, Patientory streamlines access to health data, enhances care coordination, and provides insights into health outcomes. This approach aims to democratize health data ownership, reduce healthcare costs, and improve overall patient engagement and health management.

Flare Therapeutics is a biotechnology company focused on developing small molecule medicines by exploring the biology of transcription factors. The company aims to identify 'switch sites,' which are druggable regions crucial for regulating transcription factors, to target mutations associated with various diseases. Flare's innovative approach has advanced its drug discovery efforts, resulting in a promising pipeline of programs that primarily address well-established transcription factors. Initially concentrating on precision oncology, the company's research also holds potential applications in neurology, rare genetic disorders, immunology, and inflammation. By leveraging insights from its scientific founders, Flare Therapeutics seeks to transform the treatment landscape for cancer patients and other disease areas.

Holmusk is a health data analytics company focused on enhancing treatment for mental health and chronic diseases. It develops a real-world evidence platform that integrates specialty behavioral health data with advanced analytics to provide evidence-based insights for treatment decisions. By leveraging artificial intelligence and data science, Holmusk accelerates research and improves patient outcomes through predictive algorithms. Its proprietary modeling platform enables clients to analyze real-world data, facilitating personalized medicine and driving data-driven approaches in healthcare. The company's mission is to expand evidence-based care for individuals managing behavioral health conditions, ultimately supporting the commercialization of new treatments.

At Docthus, we are dedicated to addressing the critical challenge of reducing variations in care and ensuring that every patient receives the best care each time. With our innovative platform, doctors can stay at the forefront of medical advancements, access live surgeries, participate in interactive webinars, and collaborate with a network of experts. By empowering doctors with up-to-date knowledge and fostering collaboration, we enable them to deliver the highest standard of care, ultimately improving patient outcomes and eliminating disparities in healthcare.

Orionis Biosciences is a biotechnology company focused on early-stage drug discovery and development, particularly targeting oncology and immunotherapies. Headquartered in Waltham, Massachusetts, with additional research facilities in Ghent, Belgium, the company utilizes a range of innovative technologies to create conditionally active drug modalities aimed at treating diseases with significant unmet medical needs. By inducing molecular proximity and cooperativity, Orionis enhances drug potency and precision, allowing for novel target access. Their approach facilitates the development of a diverse pipeline of drug candidates, including therapies that engage both adaptive and innate immune systems. The company collaborates with strategic partners, including VIB in Belgium, and is supported by a team of seasoned entrepreneurs and scientists, as well as a transatlantic network of investors.

Aktis Oncology is a biotechnology company pioneering the discovery and development of a new class of targeted radiopharmaceuticals to treat a broad range of solid tumor cancers. Founded and incubated by MPM Capital, the company has developed proprietary platforms to generate tumor-targeting agents with ideal properties for alpha radiotherapy. Designed for high tumor penetration and long residence time, Aktis Oncology's molecules will quickly clear other areas of the body, thereby maximizing tumor elimination while minimizing the side effects of treatment. This approach would also enable clinicians to visualize and verify target engagement prior to exposure to therapeutic radioisotopes.

Cleerly is a healthcare company whose mission is to create digital care pathways to prevent heart attacks. The company develops a new standard for coronary artery disease by integrating quality clinical science with the latest-generation AI, in order to offer actionable clinical insights to every stakeholder in the heart care pathway. Through these data-driven solutions, the company aims to provide a comprehensive solution for cardiovascular disease evaluation that offers value to the healthcare system and improves heart health for patients at risk of heart attacks.

Deciphex Limited, founded in 2017 and based in Dublin, Ireland, specializes in developing digital pathology software applications aimed at enhancing diagnostic workflows through artificial intelligence. The company offers two primary platforms: Patholytix and Diagnexia. Patholytix is designed for preclinical and toxicologic pathology, aiding pharmaceutical and clinical research organizations in optimizing safety assessments and accelerating drug development. Diagnexia facilitates rapid diagnostics by connecting global subspecialty pathologists, thereby addressing backlog issues. Both platforms automate routine tasks, allowing pathologists to concentrate on more complex cases, which ultimately leads to faster and more reliable diagnoses. Through its innovative approach, Deciphex is committed to improving patient outcomes and advancing healthcare delivery.

Parrots Inc. is a medical devices company focused on developing assistive technology for individuals with mobility and communication challenges. Their flagship product, Polly, serves as a socially assistive robot that enables users to interact more effectively with their environment. Polly operates as a hands-free device, using eye-tracking and other switches for control, allowing for seamless communication. The platform incorporates advanced artificial intelligence and machine learning to facilitate real-time communication, significantly enhancing the speed and efficiency of interactions compared to traditional devices. Parrots emphasizes five core values: communication, control, connectivity, compatibility, and caregiving. These principles guide the development of products that maximize user independence while also supporting caregivers by reducing their workload. The technology not only assists in communication but also tracks vital signs and health metrics, providing comprehensive support for users with neurological disorders and physical disabilities.

Koneksa Health Inc. is a healthcare data analytics company focused on enhancing clinical studies and disease research through the use of remotely generated patient data. The company's software, Koneksa Compare, facilitates the collection, visualization, and analysis of patient-generated data, incorporating emerging technologies such as bio-sensors, activity trackers, and mobile-based questionnaires. This platform allows pharmaceutical and biotech companies, as well as academic researchers, to make informed decisions and regulatory claims based on objective data. Koneksa also provides biometric devices that generate electronic clinical outcome assessments and offers a dashboard for monitoring patient engagement, which includes reminders for study subjects. Founded in 2013 and headquartered in New York, Koneksa has an additional office in London, United Kingdom.

Gyroscope is a clinical-stage gene therapy company that specializes in developing treatments for retinal diseases, particularly focusing on Age-related Macular Degeneration (AMD), a major cause of blindness. The company leverages advancements in understanding the complement system's role in eye diseases and uses gene therapy as a therapeutic approach. Gyroscope's lead investigational therapy, GT005, is designed to be administered as a one-time treatment under the retina, aiming to restore balance to an overactive complement system by enhancing the production of the Complement Factor I protein. Currently, GT005 is undergoing evaluation in multiple clinical trials, including a Phase I/II trial named FOCUS and two Phase II trials called EXPLORE and HORIZON. Founded in 2016 in Stevenage, Herefordshire, by Andrew Lotery, David Kavanagh, and Peter Lachmann, Gyroscope seeks to provide innovative solutions for patients suffering from retinal diseases.

Holmusk is a health data analytics company focused on enhancing treatment for mental health and chronic diseases. It develops a real-world evidence platform that integrates specialty behavioral health data with advanced analytics to provide evidence-based insights for treatment decisions. By leveraging artificial intelligence and data science, Holmusk accelerates research and improves patient outcomes through predictive algorithms. Its proprietary modeling platform enables clients to analyze real-world data, facilitating personalized medicine and driving data-driven approaches in healthcare. The company's mission is to expand evidence-based care for individuals managing behavioral health conditions, ultimately supporting the commercialization of new treatments.

Medtech Africa provides a medical platform (Forcardio) that enables caregivers to use health monitoring to manage and improve the care of their patients. We provide easy access to continuous medical care for cardiovascular disease management and care in emerging markets. We provide cost-effective and simplified tools that provide proactive, personalized, and timely information about people living with chronic conditions such as diabetes, hypertension, and heart failure.

Mekonos Inc. specializes in the design, development, and production of gene and cell therapies, focusing on a proprietary cell-engineering platform that utilizes advanced silicon technology. Founded in 2017 and based in San Francisco, the company has created an integrated system-on-a-chip, which incorporates micro-electromechanical systems (MEMS) to enable the precise injection of single cells using nanoneedles in a parallel architecture. This innovative approach aims to industrialize genome editing and enhance drug discovery and development processes. Mekonos' technology allows for scalable and reliable manufacturing of engineered therapies aimed at addressing genetic diseases, including various forms of cancer, and supports healthcare providers in delivering diverse therapeutic molecules across multiple cell types.

XOMA is at the forefront of antibody discovery and development, one of the most powerful and transformative fields of drug innovation today. Building on a pioneering proprietary pipeline, a world-class antibody discovery and development platform, plus multiple revenue streams, XOMA is creating innovative human antibody therapeutics with the potential to transform medicine and reshape people's lives.

Dunad Therapeutics is a biopharmaceutical company dedicated to developing innovative targeted protein degradation therapies. The company utilizes a small molecule platform that induces the selective degradation of disease-causing and often difficult-to-target proteins by directly modulating their stability and conformation. This approach offers a novel molecular strategy that is adaptable and operates through a mechanism of action that is not limited to specific target classes, distinguishing it from existing targeted protein degradation technologies. By focusing on oral therapies, Dunad Therapeutics aims to provide effective treatment options for challenging diseases.

Lightship is a company founded in 2018 that focuses on enhancing access, choice, and equity in clinical trials through decentralized and hybrid clinical services. By leveraging innovations in digital health and technology, Lightship aims to transform the clinical research landscape by improving patient experiences, retention, and trial diversity. The company moves beyond traditional research centers to make clinical studies more accessible, allowing medical research organizations to overcome the barriers and inefficiencies associated with conventional clinical trial models. Its mission centers on placing patients at the forefront, ensuring that clinical research is designed to meet the needs of diverse populations globally.

Arctos Medical is a spin-off from the University of Bern that focuses on developing optogenetic therapies to address common forms of blindness, particularly those caused by inherited retinal dystrophies (IRDs). Unlike traditional approaches that target rare genetic eye diseases, Arctos Medical's innovative gene therapy aims to enhance the quality of visual information transmitted to the brain, thereby offering potential treatments for patients experiencing complete vision loss. Through its research and development efforts, the company seeks to improve the lives of individuals affected by various forms of blindness.

NuvoAir AB, founded in 2015 and based in Stockholm, Sweden, is a medical technology company focused on monitoring lung function through its Air Next home spirometer. The company operates an online platform to provide its products and services. NuvoAir Medical offers a comprehensive care model that integrates advanced monitoring technology and analytics with evidence-based interventions for managing chronic heart and lung conditions. This approach emphasizes personalized care, delivered by a multidisciplinary team, and collaborates with health plans and risk-bearing entities to implement flexible payment arrangements. By focusing on value-based specialty management, NuvoAir aims to improve patient outcomes while reducing healthcare costs.

Cellerys is a Zurich-based startup conducting research on a therapy to fight multiple sclerosis.

Aspen RxHealth is a Tampa, Florida-based company that provides an online platform designed to connect licensed pharmacists with patients requiring enhanced medication services. Through its app-based technology, Aspen RxHealth facilitates direct patient care by matching pharmacists to patients based on various social and clinical criteria, such as language and medication regimens. This platform enables health plans and providers to link their patients with a community of pharmacists who can deliver clinical services tailored to individual needs. The services offered include comprehensive medication reviews and targeted medication interventions, all aimed at optimizing communication and improving patient care.

SomaLogic, Inc. is a commercial-stage company based in Boulder, Colorado, specializing in protein biomarker discovery and clinical diagnostics. The company utilizes its proprietary technology platform, SomaScan, which allows for the measurement of proteins with a precision comparable to DNA measurement. This technology enhances the understanding of the molecular bases of health and disease, surpassing traditional genomic methods. SomaLogic develops and offers SOMAmers, modified nucleic acid-based protein-binding reagents, and provides diagnostic tests and protein measurement solutions for various diseases, including those in oncology, neurology, and cardiovascular health. Their products serve multiple applications, including life sciences research, therapeutic drug development, and clinical diagnostics, making significant contributions to the fields of biological and medical sciences. Founded in 1999, SomaLogic continues to advance the capabilities of proteomics in both research and clinical settings.

Cadent Therapeutics is a precision neuroscience company based in Cambridge, Massachusetts, founded in 2010. The company specializes in developing innovative allosteric modulators of ion channels, particularly targeting the NMDA receptor, to address a range of neurological and psychiatric disorders. Its research includes subunit-selective modulators aimed at treating conditions such as depression, schizophrenia, Rett syndrome, and other autism spectrum disorders. By focusing on drug design and optimization, patient selection, and quantitative endpoints, Cadent Therapeutics seeks to create first-in-class therapeutics that can restore cognitive and motor function in patients suffering from serious neurological diseases.

Pear Therapeutics, Inc. is a healthcare company specializing in the discovery, development, and delivery of software-based therapeutics aimed at treating behavioral health disorders, including addiction, schizophrenia, anxiety, depression, and chronic insomnia. Founded in 2013 and headquartered in Boston, with an additional office in San Francisco, Pear Therapeutics offers a range of digital therapies designed to enhance treatment outcomes. Notable products include reSET, a tool for substance abuse treatment used alongside traditional therapy; reSET-O, which addresses opioid use disorder; and Somryst, aimed at chronic insomnia. The company also provides PearConnect, a patient services center that connects users with advocates, clinicians, and insurance providers to facilitate support and resource access throughout treatment. By integrating digital interventions with pharmaceuticals, Pear Therapeutics aims to improve patient engagement, clinical outcomes, and cost-effectiveness in healthcare.

Mekonos Inc. specializes in the design, development, and production of gene and cell therapies, focusing on a proprietary cell-engineering platform that utilizes advanced silicon technology. Founded in 2017 and based in San Francisco, the company has created an integrated system-on-a-chip, which incorporates micro-electromechanical systems (MEMS) to enable the precise injection of single cells using nanoneedles in a parallel architecture. This innovative approach aims to industrialize genome editing and enhance drug discovery and development processes. Mekonos' technology allows for scalable and reliable manufacturing of engineered therapies aimed at addressing genetic diseases, including various forms of cancer, and supports healthcare providers in delivering diverse therapeutic molecules across multiple cell types.

Molecular Partners is a clinical-stage biopharmaceutical company focused on developing innovative therapies for serious diseases, with a primary emphasis on oncology. The company specializes in a unique class of protein therapeutics known as DARPin® therapeutics, which are engineered to be potent, specific, and versatile. Molecular Partners has an extensive product pipeline that is organized into three main areas: ophthalmology, targeting retinal diseases such as wet age-related macular degeneration and diabetic macular edema; oncology, featuring DARPin candidates with novel mechanisms of action, including multi-DARPin compounds; and additional therapeutic areas. Through its research and development efforts, Molecular Partners aims to significantly enhance disease management and patient outcomes.

Freenome, Inc. is a biotechnology company based in South San Francisco, California, founded in 2014. It specializes in developing artificial intelligence-driven genomic solutions for the early detection of cancer. The company focuses on creating simple, non-invasive blood tests that can identify early-stage cancer and assist in treatment selection, thus enabling proactive disease management. Freenome’s multi-omics platform employs proprietary algorithms to enhance disease screening processes, aiming to facilitate timely interventions and improve treatment effectiveness. In addition to its diagnostic products, Freenome also offers clinical research services to support its mission of transforming cancer management through systematic early detection.

Science 37, Inc. is a technology-enabled clinical trial company based in Los Angeles, California, focused on advancing biomedical research through innovative, patient-centric models. The company has developed NORA, a cloud-based mobile research platform that facilitates end-to-end networked clinical trial services, allowing researchers to interact with patients and mobile nurses remotely via videos, photographs, and surveys. By utilizing a decentralized approach, Science 37 enhances patient engagement and access, making it possible to reach populations typically underserved by traditional trial methods. The company operates an extensive in-house network of telemedicine investigators and home-health nurses, enabling it to conduct a significant number of virtual interventional trials efficiently. Science 37 serves a diverse clientele, including pharmaceutical companies, device manufacturers, universities, and biotech firms, thereby contributing to the acceleration of clinical research and the development of new treatments.

AccessNow operates an information management platform focused on sharing accessibility information globally. The company has developed an interactive, crowdsourced application that allows users to find and rate the accessibility status of various locations, including restaurants, stores, and hotels. This platform aims to empower individuals with disabilities by providing accurate and up-to-date information about the accessibility of different places, thereby fostering a community dedicated to promoting inclusivity and improving access for all.

Amblyotech, LLC is an Atlanta-based company that specializes in developing electronic media therapies for the treatment of amblyopia and other ocular diseases in both adults and children. Founded in 2013, the company has created a novel application that enhances visual acuity and promotes the establishment of 3D vision, utilizing active gaming and passive video technology with 3D glasses. This innovative approach provides an alternative to traditional treatment methods such as patching, atropine drops, and surgery. Amblyotech's solutions are designed for use on various electronic devices, including tablets, computers, and smartphones. As of April 2020, Amblyotech operates as a subsidiary of Novartis AG.

The Medicines Company is focused on advancing the treatment of critical care patients through the delivery of innovative, cost-effective medicines to the worldwide hospital marketplace. The Company markets Angiomax(R) (bivalirudin) in the United States and other countries for use in patients undergoing coronary angioplasty, and Cleviprex(R) (clevidipine butyrate) injectable emulsion in the United States for the reduction of blood pressure when oral therapy is not feasible or not desirable. The Company also has two products in late stage development: cangrelor, an investigational antiplatelet agent, and oritavancin, a semi-synthetic lipoglycopeptide antibiotic. The Company's pipeline also includes a serine protease inhibitor, CU2010, in early-stage development.

Immunitas is unlocking human immunology using novel single cell analyses to develop targeted therapeutics for patients with challenging, complex cancers. Translating findings from laboratory research to meaningful clinical advances in humans is a longstanding challenge in the oncology field. Immunitas was founded to directly address this problem and unlock a variety of novel drug targets based on discovery rooted in human biology. They are pursuing this goal with a team of pioneers in these areas across their scientific founders, management, and investors. At Immunitas, they employ a single cell sequencing platform to dissect the biology of immune cells in human tumors. Their focus on human samples allows us to start with and stay closer to the most relevant and translatable biology for patients and accelerates the pace of their research. They are identifying novel, exciting oncology targets and, importantly, developing key biomarkers to guide the selection of patients who may benefit from their new drugs. They are leveraging expertise in antibody discovery and engineering to create powerful therapies that modulate these targets, and are currently advancing a number of programs toward early human studies.

SiO2 Materials Science specializes in the design and manufacturing of precision-molded plastic containers with advanced gas barrier properties comparable to glass. The company employs proprietary plasma-enhanced chemical vapor deposition (PECVD) technology to produce various medical products, including syringes, vials, and blood tubes. These containers feature low protein binding surfaces, which are crucial for enhancing the performance and safety of pharmaceuticals. By offering customized solutions with thin, transparent coatings on drug contact surfaces, SiO2 Materials Science supports clients in the development and commercialization of innovative medical products.

Ayala Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing and commercializing small molecule therapeutics for patients with rare and aggressive cancers. Founded in 2017 and based in Rehovot, Israel, the company aims to address genetically defined patient populations by targeting the tumorigenic drivers of cancer. Its lead product candidate, AL101, is an intravenous gamma secretase inhibitor currently undergoing Phase II clinical trials for the treatment of recurrent and metastatic adenoid cystic carcinoma in patients with Notch-activating mutations. Additionally, Ayala is developing AL102, an oral gamma secretase inhibitor, which is in Phase I clinical trials for desmoid tumors and has a collaboration with Novartis to further develop this compound for multiple myeloma. The company's innovative approach combines bioinformatics and next-generation sequencing to deliver targeted therapies to underserved patient populations.

Xiidra is a pharmaceutical company that specializes in developing a prescription eye drop solution aimed at treating the signs and symptoms of dry eye disease (DED). The product is a non-steroidal eye drop that specifically addresses the inflammation associated with DED, providing relief to individuals suffering from this condition. By focusing on both the symptoms and underlying causes of dry eye disease, Xiidra offers an effective treatment option for patients seeking to manage their discomfort.

Poseida Therapeutics is a clinical-stage biopharmaceutical company based in San Diego, California, dedicated to developing innovative therapeutics for patients with significant unmet medical needs. The company utilizes non-viral gene engineering technologies to create a pipeline of targeted therapies, including both autologous and allogeneic chimeric antigen receptor T cell (CAR-T) product candidates aimed at treating hematological malignancies and solid tumors. Additionally, Poseida is advancing gene therapies for rare and life-threatening conditions, such as Ornithine transcarbamylase deficiency, methylmalonic acidemia, and various genetic liver diseases. Founded in 2014, Poseida is committed to addressing critical health challenges through its focused research and development efforts.

TestCard is a healthcare technology company focused on enhancing the accessibility and accuracy of non-invasive testing. Its innovative platform allows users to conduct medical tests at home by combining traditional laboratory testing methods with mobile technology. By embedding urine samples into a proprietary testing card, users can obtain clinical-grade results through a mobile application. This approach not only ensures more accurate and reliable readings compared to traditional visual assessments but also facilitates immediate access to healthcare solutions. Additionally, TestCard's digital connectivity enables integration with hospital electronic patient record systems, streamlining the route to treatment through established healthcare partnerships.

Xealth Inc. operates a digital health prescribing platform that allows clinicians to integrate, prescribe, and monitor digital health tools directly from electronic health record (EHR) workflows. Founded in 2016 and based in Seattle, Washington, the platform facilitates patient engagement by enabling care teams to order appropriate digital health tools and programs, which can be sent to patients via email or patient portals. In addition to managing digital health prescriptions, the platform supports patient education and offers non-clinical services such as ride shares and food delivery. This comprehensive approach allows clinicians to monitor patient activity and engagement, ultimately enhancing the overall effectiveness of digital health initiatives within healthcare systems.

Anthos Therapeutics is a biopharmaceutical company that specializes in the treatment of cardiovascular and metabolic diseases. The company was founded by a world-class executive team with extensive experience in the development and commercialization of CVM disease therapies.

Pear Therapeutics, Inc. is a healthcare company specializing in the discovery, development, and delivery of software-based therapeutics aimed at treating behavioral health disorders, including addiction, schizophrenia, anxiety, depression, and chronic insomnia. Founded in 2013 and headquartered in Boston, with an additional office in San Francisco, Pear Therapeutics offers a range of digital therapies designed to enhance treatment outcomes. Notable products include reSET, a tool for substance abuse treatment used alongside traditional therapy; reSET-O, which addresses opioid use disorder; and Somryst, aimed at chronic insomnia. The company also provides PearConnect, a patient services center that connects users with advocates, clinicians, and insurance providers to facilitate support and resource access throughout treatment. By integrating digital interventions with pharmaceuticals, Pear Therapeutics aims to improve patient engagement, clinical outcomes, and cost-effectiveness in healthcare.

CellforCure is an innovative company specializing in advanced therapy medicinal products, particularly in the field of cell and gene therapy. It operates a cell therapy business that caters to hospitals and clinics, providing essential medicinal products designed to enhance patient care. Through its focus on advanced therapeutic solutions, CellforCure plays a significant role in the evolving landscape of medical treatments, addressing the growing demand for effective and targeted therapies.

Endocyte, Inc. is a biopharmaceutical company focused on developing receptor-targeted therapies for cancer and inflammatory diseases. Headquartered in West Lafayette, Indiana, the company creates innovative small molecule drug conjugates (SMDCs) and companion imaging agents. Among its key products, Vintafolide is in Phase IIb clinical trials for non-small cell lung cancer, while EC1456 and EC1169 are in Phase I trials for advanced solid tumors and metastatic castration-resistant prostate cancer, respectively. Additionally, Endocyte is developing several pre-clinical candidates, including EC2629 for cancer treatment and EC2319 for inflammatory diseases. The company has established collaborations with Purdue Research Foundation and other organizations to advance its pipeline. Founded in 1995, Endocyte operates as a subsidiary of Novartis AG.

Coda Biotherapeutics, Inc. is a biotechnology company focused on developing innovative treatments for neurological disorders. The company specializes in chemogenetic technology, which allows for precise modulation of neuronal activity through gene therapy. By using viral vectors, Coda Biotherapeutics introduces engineered neurotransmitter receptors into specific neuronal populations. These receptors are designed to respond to a proprietary small molecule, enabling targeted control of neuronal functions. This approach aims to effectively treat conditions such as neuropathic pain, epilepsy, and movement disorders, offering a potential advancement over traditional therapies. Founded in 2014, Coda Biotherapeutics is headquartered in San Francisco, California.

Mekonos Inc. specializes in the design, development, and production of gene and cell therapies, focusing on a proprietary cell-engineering platform that utilizes advanced silicon technology. Founded in 2017 and based in San Francisco, the company has created an integrated system-on-a-chip, which incorporates micro-electromechanical systems (MEMS) to enable the precise injection of single cells using nanoneedles in a parallel architecture. This innovative approach aims to industrialize genome editing and enhance drug discovery and development processes. Mekonos' technology allows for scalable and reliable manufacturing of engineered therapies aimed at addressing genetic diseases, including various forms of cancer, and supports healthcare providers in delivering diverse therapeutic molecules across multiple cell types.

AveXis, now known as Novartis Gene Therapies, is a biotechnology company focused on developing and commercializing gene therapies aimed at treating rare and life-threatening neurological genetic disorders. Acquired by Novartis in 2018, the company specializes in motor neuron cell-targeted gene replacement therapies for conditions such as spinal muscular atrophy, Rett syndrome, and amyotrophic lateral sclerosis. By addressing these severe diseases, which often result in progressive muscle weakness, paralysis, and death, AveXis plays a crucial role in enhancing treatment options for affected patients and their families.

Pear Therapeutics, Inc. is a healthcare company specializing in the discovery, development, and delivery of software-based therapeutics aimed at treating behavioral health disorders, including addiction, schizophrenia, anxiety, depression, and chronic insomnia. Founded in 2013 and headquartered in Boston, with an additional office in San Francisco, Pear Therapeutics offers a range of digital therapies designed to enhance treatment outcomes. Notable products include reSET, a tool for substance abuse treatment used alongside traditional therapy; reSET-O, which addresses opioid use disorder; and Somryst, aimed at chronic insomnia. The company also provides PearConnect, a patient services center that connects users with advocates, clinicians, and insurance providers to facilitate support and resource access throughout treatment. By integrating digital interventions with pharmaceuticals, Pear Therapeutics aims to improve patient engagement, clinical outcomes, and cost-effectiveness in healthcare.

Homology Medicines, Inc. is a genetic medicines company dedicated to transforming the lives of patients suffering from rare genetic diseases with significant unmet medical needs by curing the underlying cause of the disease. Homology’s proprietary platform is designed to utilize its human hematopoietic stem cell-derived adeno-associated virus vectors (AAVHSCs) to precisely and efficiently deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing modality across a broad range of genetic disorders. Homology has a management team with a successful track record of discovering, developing and commercializing therapeutics with a particular focus on rare diseases and a robust intellectual property portfolio with issued composition of matter patents in the United States for its suite of 15 AAVHSCs. Homology believes that its compelling preclinical data, scientific expertise, product development strategy, manufacturing capabilities and intellectual property position it as a leader in the development of genetic medicines.

Anaeropharma Science, Inc. is a biopharmaceutical company based in Chiyoda, Japan, founded in 2004. The company specializes in developing therapeutics aimed at treating solid cancers characterized by hypoxic environments. Utilizing its proprietary platform technology, which involves recombinant Bifidobacterium, Anaeropharma has created innovative therapies such as APS001F, an anticancer solution, and FGF2, which addresses ischemia. Its approach involves genetically enhanced bacteria that thrive in the oxygen-deprived areas of tumors, where they convert a pro-drug into a cytotoxic agent. This technology enables healthcare professionals to provide more effective and safer treatments for various cancers and related hypoxic conditions.

Gamida Cell is a clinical-stage biopharmaceutical company focused on developing innovative cell therapies for patients with blood cancers and serious hematologic diseases. The company's lead product candidate, omidubicel, is an advanced therapy utilizing nicotinamide-expanded hematopoietic stem cells, currently undergoing Phase 3 trials for patients with high-risk hematologic malignancies and a Phase 1/2 trial for severe aplastic anemia. Additionally, Gamida Cell is advancing GDA-201, a natural killer cell-based immunotherapy that is in Phase 1/2 studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. Founded in 1998 and headquartered in Jerusalem, Israel, the company employs a proprietary expansion platform that enhances the properties of nicotinamide to optimize allogeneic cell sources, including umbilical cord blood-derived cells.

ONL Therapeutics is a biopharmaceutical company focused on developing innovative therapeutics to protect and improve vision in patients with retinal diseases and conditions. Founded in 2006 and headquartered in Ann Arbor, Michigan, the company specializes in creating photoreceptor protective agents that target the FAS apoptotic pathway. Its drug programs aim to safeguard photoreceptors, thereby enhancing outcomes for patients undergoing surgeries related to retinal detachment and other serious vision-threatening issues. Through its research and development efforts, ONL Therapeutics seeks to provide effective solutions for preserving sight and improving the quality of life for individuals affected by these conditions.

Semma Therapeutics, Inc. is focused on developing innovative cell therapies for patients with Type 1 diabetes, who typically rely on insulin injections. The company was founded based on groundbreaking research by Professor Douglas Melton, which enabled the generation of functional, insulin-producing beta cells in the laboratory. This technology has been exclusively licensed to Semma Therapeutics, and the company aims to combine these proprietary cells with advanced devices to create a functional replacement for the missing beta cells without the need for immunosuppression. Headquartered in Cambridge, Massachusetts, with an additional office in Boston, Semma Therapeutics operates as a subsidiary of Vertex Pharmaceuticals and is dedicated to advancing this new therapeutic option to improve the lives of diabetes patients.

Encore Vision is a Fort Worth, Texas-based company that specializes in developing ophthalmic therapeutics aimed at treating presbyopia. Established in 2000, the company has made significant advancements in its technology, which involves an eye drop treatment designed to reduce lens stiffness and enhance flexibility, thereby improving near vision. Encore Vision has been supported by ophthalmologists and optometrists during its development phase, resulting in a robust patent portfolio that includes an issued U.S. patent, a notice of allowance for a second patent, and over 40 pending applications. The company has successfully completed in-vivo proof of concept studies in animal models and is progressing toward clinical trials for human applications. In addition to its therapeutic focus, Encore Vision also designs and supplies a range of eyewear products, including lenses and frames, and facilitates inquiries through its online platform.

Selexys Pharmaceuticals Corporation (Selexys) is a privately held company that is developing drugs to treat inflammatory and thrombotic diseases. They are targeting the underlying disease mechanism for these disorders. Their target is the adhesion of white blood cells to sites of inflammation mediated by the binding of two proteins, P-selectin and PSGL-1. The company is in preclinical development of humanized antibodies to P-selectin and PSGL-1 for the treatment of acute and chronic inflammatory and thrombotic disorders. Unregulated inflammatory processes play a major role in the harmful effects of multiple inflammatory disorders.

YourBio Health is focused on revolutionizing the blood sampling and testing process to enhance the interaction between diagnostic medicine and healthcare consumers. The company has developed a blood collection device that allows for convenient and virtually painless blood testing. Utilizing its proprietary Touch Activated Phlebotomy (TAP) technology, the device enables users to collect blood from their upper arm with a simple push of a button, facilitating easy and rapid diagnostic testing in various settings. This innovative approach aims to eliminate barriers in acquiring critical diagnostic information, thereby promoting informed healthcare delivery and empowering patients to take an active role in their well-being. By integrating TAP technology with a range of diagnostic assays, YourBio Health seeks to improve both patient and clinician experiences in the healthcare landscape.

Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company based in Hayward, California, focused on developing innovative cancer therapies. The company’s product pipeline includes several key candidates, such as AB928, a dual A2a/A2b adenosine receptor antagonist in Phase 1b/2 trials, and Zimberelimab, an anti-PD-1 monoclonal antibody currently being evaluated in Phase Ib studies. Additionally, Arcus is advancing AB154, an anti-TIGIT monoclonal antibody in Phase 2 trials, and AB680, a small-molecule CD73 inhibitor in Phase 1/1b studies for the treatment of metastatic pancreatic cancer. The company collaborates with Strata Oncology and AstraZeneca to enhance the development of its therapies and has strategic partnerships with firms like WuXi Biologics. Founded in 2015, Arcus aims to leverage emerging insights in immunology to create effective cancer treatments across various indications, including non-small cell lung cancer and pancreatic cancer.

IFM Therapeutics is a provider of small molecule that module novel targets in the innate immune system. The company and its academic collaborators combine unparalleled expertise in innate immunity with seasoned drug discovery and development professionals. Its subsidiary IFM Due is focused on the discovery and developing antagonists of the cGAS/STING pathway for the treatment of inflammation, neuroinflammation, autoimmunity and cancer. IFM Discovery, a newly financed incubator entity within the IFM enterprise, is prosecuting a basket of genetically-validated targets as next-generation therapies for inflammation, neuroinflammation, autoimmunity and fibrosis

COTA was founded in 2011 by doctors, engineers, and data scientists to create clarity from fragmented and often-inaccessible real world data. By using proprietary technology, advanced analytics and deep expertise to organize complex data, COTA provides a comprehensive picture of cancer that can be used to advance care and research.

Caribou Biosciences, Inc. is a biotechnology company focused on cellular engineering and genome editing using CRISPR technology. Established in 2011 and based in Berkeley, California, the company leverages its CRISPR-Cas gene editing platform to facilitate precise modifications in DNA across various applications. These include developing therapeutics for human and animal health, creating disease models, enhancing agricultural traits, and advancing industrial biotechnology. Caribou Biosciences is particularly dedicated to the development of genome-edited cell therapies, including allogeneic CAR-T and CAR-NK cell therapies, aimed at improving outcomes for patients with severe diseases. The company’s innovative approach combines CRISPR with guide RNA to enable targeted DNA alterations, thereby contributing to advancements in both therapeutic development and biological research.

Rani Therapeutics, LLC is a clinical-stage biotherapeutics company that focuses on the development of oral delivery technologies for large drug molecules, such as peptides, proteins, and antibodies. The company has created the RaniPill capsule, a proprietary and patented platform designed to administer biologics orally, offering a convenient alternative to traditional subcutaneous or intravenous injections. This capsule is engineered to deliver precise therapeutic doses upon reaching the small intestine. Rani Therapeutics is advancing various treatments, including TNFa inhibitors for inflammatory disorders, parathyroid hormone for osteoporosis, and human growth hormone for growth deficiencies. Additionally, their portfolio includes therapies for multiple sclerosis, type II diabetes, and various inflammatory diseases. Founded in 2012 and based in San Jose, California, Rani Therapeutics has conducted several preclinical and clinical studies to assess the safety and effectiveness of its technologies, building a robust intellectual property portfolio in the process.

Pear Therapeutics, Inc. is a healthcare company specializing in the discovery, development, and delivery of software-based therapeutics aimed at treating behavioral health disorders, including addiction, schizophrenia, anxiety, depression, and chronic insomnia. Founded in 2013 and headquartered in Boston, with an additional office in San Francisco, Pear Therapeutics offers a range of digital therapies designed to enhance treatment outcomes. Notable products include reSET, a tool for substance abuse treatment used alongside traditional therapy; reSET-O, which addresses opioid use disorder; and Somryst, aimed at chronic insomnia. The company also provides PearConnect, a patient services center that connects users with advocates, clinicians, and insurance providers to facilitate support and resource access throughout treatment. By integrating digital interventions with pharmaceuticals, Pear Therapeutics aims to improve patient engagement, clinical outcomes, and cost-effectiveness in healthcare.

C4 Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapeutic candidates that target and eliminate disease-causing proteins, primarily for the treatment of cancer and neurodegenerative disorders. The company's lead product candidate, CFT7455, is an orally bioavailable degrader designed to target IKZF1/3 for multiple myeloma and other lymphomas. Additionally, C4 is advancing CFT8634, which targets BRD9 for specific solid tumors, alongside programs aimed at genetically defined resistant solid tumors. C4 Therapeutics utilizes its proprietary Degronimid platform, which allows for the selective degradation of proteins through the natural ubiquitin/proteasome system, potentially addressing previously undruggable targets while minimizing drug resistance. The company has formed strategic collaborations with major industry players, and it aims to make a significant impact on the treatment landscape through its advanced protein degradation science and multiple development programs. Founded in 2015 and headquartered in Watertown, Massachusetts, C4 Therapeutics continues to innovate in the field of targeted therapy.

Admune Therapeutics LLC is a clinical-stage biotechnology company based in Danvers, Massachusetts, specializing in the development of cytokine therapy drugs aimed at treating various forms of cancer. The company's primary focus is on heterodimeric IL-15, an IL-15 agonist that has potential applications in cancer immunotherapy. As of October 2015, Admune operates as a subsidiary of Novartis International AG and offers medical consultancy alongside its core therapeutic developments.

Intellia Therapeutics is a genome editing company headquartered in Cambridge, Massachusetts, that specializes in developing innovative therapeutics using the CRISPR/Cas9 technology. The company focuses on in vivo programs targeting liver diseases such as transthyretin amyloidosis and hereditary angioedema, as well as conditions like primary hyperoxaluria Type 1, alpha-1 antitrypsin deficiency, and Hemophilia B. Additionally, Intellia's ex vivo pipeline includes engineered cell therapies aimed at treating various oncological and autoimmune diseases. The company has entered into collaborations with notable organizations, including Novartis and Regeneron Pharmaceuticals, to advance its research and development efforts. Founded in 2014, Intellia Therapeutics is committed to addressing severe and life-threatening diseases through its comprehensive intellectual property platform and a broad range of clinical development programs.

Spinifex is backed by a syndicate of experienced life science investors including Novo Ventures, Canaan Partners, GBS Venture Partners, Brandon Capital Partners, Uniseed and UniQuest. Founded in 2005, Spinifex raised an initial AU$3.25 million in Series A fundraising and a total of AU$23.08 in Series B funding support the further development of EMA401. Spinifex raised a US$45 million in a Series C round led by Novo Ventures and including additional new investor Canaan Partners in 2014. Spinifex has a strong portfolio of intellectual property around its lead compound EMA01, follow on candidates and the use of AT2 receptor antagonists to treat both neuropathic & inflammatory pain and restore nerve conduction velocity deficits, including granted US, European, Japanese, Chinese, Australian and New Zealand patents.

Rani Therapeutics, LLC is a clinical-stage biotherapeutics company that focuses on the development of oral delivery technologies for large drug molecules, such as peptides, proteins, and antibodies. The company has created the RaniPill capsule, a proprietary and patented platform designed to administer biologics orally, offering a convenient alternative to traditional subcutaneous or intravenous injections. This capsule is engineered to deliver precise therapeutic doses upon reaching the small intestine. Rani Therapeutics is advancing various treatments, including TNFa inhibitors for inflammatory disorders, parathyroid hormone for osteoporosis, and human growth hormone for growth deficiencies. Additionally, their portfolio includes therapies for multiple sclerosis, type II diabetes, and various inflammatory diseases. Founded in 2012 and based in San Jose, California, Rani Therapeutics has conducted several preclinical and clinical studies to assess the safety and effectiveness of its technologies, building a robust intellectual property portfolio in the process.

Caribou Biosciences, Inc. is a biotechnology company focused on cellular engineering and genome editing using CRISPR technology. Established in 2011 and based in Berkeley, California, the company leverages its CRISPR-Cas gene editing platform to facilitate precise modifications in DNA across various applications. These include developing therapeutics for human and animal health, creating disease models, enhancing agricultural traits, and advancing industrial biotechnology. Caribou Biosciences is particularly dedicated to the development of genome-edited cell therapies, including allogeneic CAR-T and CAR-NK cell therapies, aimed at improving outcomes for patients with severe diseases. The company’s innovative approach combines CRISPR with guide RNA to enable targeted DNA alterations, thereby contributing to advancements in both therapeutic development and biological research.

BioLineRx Ltd. is a clinical-stage biopharmaceutical development company based in Modi’in, Israel, specializing in oncology. The company’s pipeline includes two primary therapeutic candidates: BL-8040, a novel peptide designed for treating solid tumors, hematological malignancies, and facilitating stem cell mobilization, and AGI-134, an immuno-oncology agent targeted at solid tumors. Additionally, BioLineRx offers BL-5010, a proprietary pen-like applicator intended for the non-surgical removal of skin lesions. The company actively collaborates with prominent organizations such as MSD, MD Anderson Cancer Center, and Genentech to explore innovative treatment combinations and advance its clinical studies. Established in 2003, BioLineRx focuses on addressing unmet medical needs in the pharmaceutical sector.

Intellia Therapeutics is a genome editing company headquartered in Cambridge, Massachusetts, that specializes in developing innovative therapeutics using the CRISPR/Cas9 technology. The company focuses on in vivo programs targeting liver diseases such as transthyretin amyloidosis and hereditary angioedema, as well as conditions like primary hyperoxaluria Type 1, alpha-1 antitrypsin deficiency, and Hemophilia B. Additionally, Intellia's ex vivo pipeline includes engineered cell therapies aimed at treating various oncological and autoimmune diseases. The company has entered into collaborations with notable organizations, including Novartis and Regeneron Pharmaceuticals, to advance its research and development efforts. Founded in 2014, Intellia Therapeutics is committed to addressing severe and life-threatening diseases through its comprehensive intellectual property platform and a broad range of clinical development programs.

Raze Therapeutics is leading the discovery and development of a new class of oncology therapeutics that target key metabolic pathways. Raze is advancing a pipeline of therapeutics based on new biological insights into how cancer cells reprogram metabolism to activate central anabolic processes essential for tumors to grow and survive.

CoStim Pharmaceuticals Inc. operates as a biotechnology company. It develops antibody agents for treatment of cancer. The company was incorporated in 2011 and is based in Boston, Massachusetts.

Proteus Digital Health, Inc. was a digital medicines company that developed innovative healthcare solutions by integrating pharmaceuticals with technology. Founded in 2001 and headquartered in Redwood City, California, the company aimed to create a new category of pharmaceuticals known as Digital Medicines. This approach involved ingestible sensors that communicated medication adherence, wearable devices that monitored physiological responses, and mobile applications designed to support patient self-care and facilitate communication with healthcare providers. The overarching goal was to empower patients and enhance the ability of physicians and health systems to manage risks effectively and achieve reliable health outcomes. Despite its advancements in digital health technology, Proteus Digital Health filed for Chapter 11 bankruptcy and ceased operations on November 30, 2020.